Why Windtree Therapeutics Stock Is Getting Hammered - Quantisnow
| WINT Stock | USD 0.13 0.01 7.14% |
Slightly above 60% of Windtree Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Windtree Therapeutics suggests that many traders are alarmed. Windtree Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Windtree Therapeutics' earnings reports, geopolitical events, and overall market trends.
Why Windtree Therapeutics Stock Is Getting Hammered Quantisnow
Read at news.google.com
 |
Windtree Therapeutics Fundamental Analysis
We analyze Windtree Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Windtree Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Windtree Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Windtree Therapeutics is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Windtree Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Windtree Therapeutics stock to make a market-neutral strategy. Peer analysis of Windtree Therapeutics could also be used in its relative valuation, which is a method of valuing Windtree Therapeutics by comparing valuation metrics with similar companies.
Peers
Windtree Therapeutics Related Equities
| KPRX | Kiora Pharmaceuticals | 4.20 | ||||
| MTVA | MetaVia | 3.23 | ||||
| LIXT | Lixte Biotechnology | 3.02 | ||||
| PALI | Palisade Bio | 2.74 | ||||
| ENTO | Entero Therapeutics, | 1.46 | ||||
| DRMA | Dermata Therapeutics | 1.48 |
Additional Tools for Windtree Stock Analysis
When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.